CLAIMS AMENDMENTS

1-64 (Canceled).

65. (Currently amended) A method of inducing rapid onset and long lasting sedation and analgesia in an animal, comprising administering to the animal a pharmaceutically effective amount of a composition consisting essentially of a guanidine derivative selected from the group consisting of guanabenz, guanabenz acetate, guanoxabenz, clonidine, guanacline, guanadrel, guanazodine, guanethidine, guanfacine, guanochlor, and guanoxan.

66. (Previously presented) The method of claim 65, wherein the guanadine derivative is guanabenz acetate or pharmaceutically acceptable derivative thereof.

67. (Previously presented) The method of claim 65, wherein the administration is oral.

68. (Previously presented) The method of claim 65, wherein the administration is intravenous.

69. (Previously presented) The method of claim 65, wherein the administration is intramuscular.

70. (Previously presented) The method of claim 65, wherein the animal is selected from the group consisting of equine, canine, feline, bovine, caprine, porcine and ovine.

71. (Previously presented) The method of claim 65, wherein the animal is an equine.

72. (Previously presented) The method of claim 65 wherein the rapid onset sedation and analgesia is induced in a standing animal.

73. (Previously presented) The method of claim 65, further comprising the step of selectively reversing or controlling the level of analgesia and sedation in the animal comprising administering a pharmaceutically effective amount of α adrenergic antagonist to the animal.

74. (Previously presented) The method of claim 73 wherein the α adrenergic antagonist is selected from the group consisting of yohimbine, rauwolscine, idazoxan and atepamezole.

75. (Previously presented) The method of claim 65, wherein the pharmaceutically effective amount of the guanidine derivative is between about 0.05 mg/kg and about 0.50 mg/kg.

76. (Previously presented) The method of claim 65, wherein the pharmaceutically effective amount of the guanidine derivative is about 0.25 mg/kg.

77. (Previously presented) The method of claim 65, wherein the guanidine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof and the pharmaceutically effective amount is between about 0.05 mg/kg and about 0.50 mg/kg.

78. (Previously presented) The method of claim 65, wherein the guanidine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof and the pharmaceutically effective amount is about 0.25 mg/kg.

79. (Previously presented) The method of claim 65, wherein the guanidine derivative is an α adrenergic agonist.

80-91 (Canceled).